Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
Interventions: Atorvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hyperlipidemia
Interventions: Vitamin D3, Placebo; Dietary Supplement · Other
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years to 88 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Cardiovascular Disease
Interventions: bococizumab (PF-04950615), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 518
States / cities: Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more

Conditions: Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder, Hypertriglyceridemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (sHTG), Mixed Hyperlipemia, Hypercholesterolaemia
Interventions: CTX310; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Hialeah, Florida • Jacksonville, Florida • Orlando, Florida + 5 more

Conditions: Hypercholesterolemia, Familial
Interventions: Torcetrapib/atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Disease, Hypertension, Hyperlipidemia, Diabetes Mellitus, Osteoarthritis, COPD, Cardiovascular Disease
Interventions: Patient Primer Tool; Behavioral
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Hypercholesterolemia
Interventions: P-OM3, Placebo; Drug
Lead sponsor: Provident Clinical Research; Other
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Hyperlipidemia
Interventions: Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more

Conditions: Hyperlipidemia
Interventions: Capros dietary supplement; Dietary Supplement
Lead sponsor: Chandan K Sen; Other
Eligibility: 21 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Overweight, Pre-hypertension, Hypertension, Hypercholesterolemia, Glucose Intolerance
Interventions: Mediterranean diet, Control group; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 30 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypercholesterolemia, Familial Hypercholesterolemia
Interventions: Enclitide Chloride, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 20
States / cities: Beverly Hills, California • Sacramento, California • Santa Ana, California + 17 more

Conditions: Hypercholesterolemia, LDL Cholesterol
Interventions: LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Hypercholesterolemia
Interventions: colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 14
States / cities: Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more

Conditions: Hypertriglyceridemia
Interventions: warfarin, omefas, omega-3-acid ethyl esters; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes Mellitus, Hypertension, Coronary Artery Disease, Atrial Fibrillation, Stroke
Interventions: PHCVRS Intervention, Personal Health Record; Other
Lead sponsor: Korey Kennelty; Other
Eligibility: 50 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 12
States / cities: Akron, Iowa • Belmond, Iowa • Cedar Rapids, Iowa + 9 more

Conditions: Hypercholesterolemia, Dyslipidemias
Interventions: Atorvastatin injection; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Hyperlipidemia, Mixed Dyslipidemia
Interventions: Niacin ER/Simvastatin Tablets, atorvastatin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 21 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 46
States / cities: Anaheim, California • Huntington Park, California • Long Beach, California + 43 more

Conditions: Diabetes Mellitus, Dyslipidemia, Hypercholesterolemia, Cardiovascular Disease
Interventions: Decision Aid Statin Choice; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Evolocumab, Standard of Care; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 3,681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 107
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more

Conditions: Severe Hypertriglyceridemia
Interventions: placebo, omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: National City, California • Sacramento, California • Manchester, Connecticut + 25 more

Conditions: Hyperlipidemias, Hypertriglyceridemia, Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions: CAT-2003, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Indianapolis, Indiana • Auburn, Maine + 1 more

Conditions: Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 39
States / cities: Anaheim, California • Huntington Beach, California • Los Angeles, California + 36 more

Conditions: Peritoneal Dialysis, Hypertriglyceridemia
Interventions: Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution; Drug
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Santa Clara, California • Michigan City, Indiana • Lincoln, Nebraska

Search by objective public record fields.

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

A Pilot Study to Improve Patient-Doctor Communication

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

Short Term Intermittent Fasting and Mediterranean Diet

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

Epanova® for Lowering Very High Triglycerides

Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients